Literature DB >> 28546063

Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials.

Andrea Casadei Gardini1, Giovanni Luca Frassineti2, Francesco Giuseppe Foschi3, Giorgio Ercolani4, Paola Ulivi5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28546063     DOI： 10.1016/j.dld.2017.04.022

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN： 1590-8658            Impact factor:   4.088


× No keyword cloud information.
  6 in total

1.  Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience.

Authors:  Margherita Rimini; Changhoon Yoo; Sara Lonardi; Gianluca Masi; Alessandro Granito; Yeonghak Bang; Mario Domenico Rizzato; Caterina Vivaldi; Luca Ielasi; Hyung-Don Kim; Francesca Bergamo; Francesca Salani; Simona Leoni; Baek-Yeol Ryoo; Min-Hee Ryoo; Valentina Burgio; Stefano Cascinu; Andrea Casadei-Gardini
Journal:  Target Oncol       Date:  2021-09-07       Impact factor: 4.493

2.  Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience.

Authors:  Giulia Rovesti; Giulia Orsi; Andrikou Kalliopi; Caterina Vivaldi; Giorgia Marisi; Luca Faloppi; Francesco Giuseppe Foschi; Nicola Silvestris; Irene Pecora; Giuseppe Aprile; Eleonora Molinaro; Laura Riggi; Paola Ulivi; Matteo Canale; Alessandro Cucchetti; Emiliano Tamburini; Giorgio Ercolani; Lorenzo Fornaro; Pietro Andreone; Patrizia Zavattari; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
Journal:  Gastrointest Tumors       Date:  2019-09-12

3.  Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status.

Authors:  Shou-Wu Lee; Teng-Yu Lee; Yen-Chun Peng; Sheng-Shun Yang; Hong-Zen Yeh; Chi-Sen Chang
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

4.  Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study.

Authors:  Jingjun Huang; Yongjian Guo; Wensou Huang; Xiaotao Hong; Yi Quan; Liteng Lin; Jingwen Zhou; Licong Liang; Yaqin Zhang; Juan Zhou; Mingyue Cai; Kangshun Zhu
Journal:  J Hepatocell Carcinoma       Date:  2022-03-10

5.  Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2022-06-13       Impact factor: 12.430

Review 6.  Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

Authors:  Giorgia Marisi; Alessandro Cucchetti; Paola Ulivi; Matteo Canale; Giuseppe Cabibbo; Leonardo Solaini; Francesco G Foschi; Serena De Matteis; Giorgio Ercolani; Martina Valgiusti; Giovanni L Frassineti; Mario Scartozzi; Andrea Casadei Gardini
Journal:  World J Gastroenterol       Date:  2018-09-28       Impact factor: 5.742
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.